{"id":"retagliptin-henagliflozein-metformin-xr","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Abdominal pain"},{"rate":"5-10%","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL494397","moleculeType":"Small molecule","molecularWeight":"165.63"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Retagliptin is a DPP-4 inhibitor, Henagliflozein is a GLP-1 receptor agonist, and metformin XR is a biguanide. By combining these mechanisms, the drug aims to improve glycemic control in patients with type 2 diabetes.","oneSentence":"Retagliptin, Henagliflozein, and metformin XR work together to lower blood sugar levels by enhancing insulin secretion and suppressing glucagon release, and also by decreasing glucose reabsorption in the kidneys.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:31:52.880Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT04667143","phase":"PHASE3","title":"Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-01","conditions":"Diabetes Mellitus, Type II","enrollment":760}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Retagliptin, Henagliflozein, metformin XR","genericName":"Retagliptin, Henagliflozein, metformin XR","companyName":"Jiangsu HengRui Medicine Co., Ltd.","companyId":"jiangsu-hengrui-medicine-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Retagliptin, Henagliflozein, and metformin XR work together to lower blood sugar levels by enhancing insulin secretion and suppressing glucagon release, and also by decreasing glucose reabsorption in the kidneys. Used for Treatment of type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}